Last edition
News about "Newron Strengthens Evenamide IP "
Newron Strengthens Evenamide IP Portfolio with New European Patent Approval
Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on developing innovative therapies for disorders of the central and peripheral nervous system, announced that the European Patent Office (EPO) has granted an additional patent covering its lead drug candidate, evenamide.
Newron Strengthens Evenamide IP | 08/01/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members